IO-TKI Treatment Regimens in the Treatment of mRCC

Opinion
Video

Panelists discuss how immunotherapy–tyrosine kinase inhibitor (IO-TKI) combination regimens have revolutionized the treatment landscape for metastatic renal cell carcinoma (mRCC) by offering improved response rates, survival outcomes, and quality of life compared with traditional monotherapies.

Recent Videos
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
2 experts are featured in this series.
4 experts in this video
Related Content